Trends in statin utilization and ischemic heart disease mortality in Lithuania and Sweden, 2000-2020.


Journal

Upsala journal of medical sciences
ISSN: 2000-1967
Titre abrégé: Ups J Med Sci
Pays: Sweden
ID NLM: 0332203

Informations de publication

Date de publication:
2024
Historique:
received: 05 12 2023
revised: 26 03 2024
accepted: 31 03 2024
medline: 12 6 2024
pubmed: 12 6 2024
entrez: 12 6 2024
Statut: epublish

Résumé

To compare statin utilization and ischemic heart disease (IHD) mortality trends in Lithuania and Sweden and to assess correlations between the total utilization of statins and IHD mortality. An ecological study assessing time trends in statin utilization (DDDs per 1000 inhabitants per day; DDD/TID) and IHD mortality in Lithuania and Sweden between 2000 and 2020. Statin utilization data in Lithuania were wholesale trade data, and Swedish data were drugs dispensed at pharmacies. IHD mortality data were extracted from national databases as rates per 100 000 inhabitants. Associations between statin utilization and IHD mortality in Lithuania and Sweden were examined using Spearman's rank and Pearson's correlation coefficients, respectively. Statin utilization increased from 16.8 to 135.8 DDD/TID in Sweden and from 0.2 to 61.8 DDD/TID in Lithuania between 2000 and 2020. Medium intensity was the most common statin dosage in Lithuania, while Sweden used more high intensity than moderate-intensity statins from 2017. IHD mortality in Lithuania remained high between 2000 and 2020 (from 359.1 to 508.8 deaths per 100 000 population), while it decreased markedly in Sweden (from 226.87 to 88.7 deaths per 100 000 population). IHD mortality and statin utilization were inversely correlated in Sweden (r = -0.993, Despite the growing statin utilization in both countries, Lithuania recorded a slight increase in IHD mortality rates unlike the situation in Sweden. This indicates room for improvement in the management of modifiable cardiovascular risk factors in Lithuania including how statins are prescribed and used in clinical practice.

Identifiants

pubmed: 38863727
doi: 10.48101/ujms.v129.10412
pii: 10412
pmc: PMC11165250
doi:

Substances chimiques

Hydroxymethylglutaryl-CoA Reductase Inhibitors 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024 The Author(s).

Déclaration de conflit d'intérêts

The authors declare no conflict of interest.

Auteurs

Indre Treciokiene (I)

Pharmacy and Pharmacology Centre, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.

Kamile Daukintyte (K)

Pharmacy and Pharmacology Centre, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.

Paul Hjemdahl (P)

Department of Medicine Solna, Clinical Epidemiology Unit, Karolinska Institute and Clinical Pharmacology, Karolinska University Hospital, Stockholm, Sweden.

Björn Wettermark (B)

Pharmacy and Pharmacology Centre, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.
Department of Pharmacy, Faculty of Pharmacy, Uppsala University, Uppsala, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH